Results 201 to 210 of about 943,135 (348)

Assessingin vitrocombinations of antifungal drugs against yeasts and filamentous fungi: comparison of different drug interaction models [PDF]

, 2005
Joseph Meletiadis, Paul E. Verweij, D. T. A. Te Dorsthorst, Jacques F. Meis, Johan W. Mouton   +4 more
openalex   +1 more source

Molecular imaging predicts trastuzumab‐deruxtecan (T‐DXd) response in head and neck cancer xenograft models

Molecular Oncology, EarlyView.
Trastuzumab‐deruxtecan, a HER2‐targeting antibody‐drug conjugate, shows promising antitumor activity in head and neck squamous cell carcinoma with low HER2 expression. In vitro and in vivo studies demonstrated dose‐dependent cell death and tumor growth reduction in low HER2‐expressing cell lines, which correlated with drug accumulation measured using a
Abdullah Bin Naveed, Lucas Mani, Muhammad Bilal Mirza, Ashtyn McAdoo, Takahito Kondo, Hidenori Tanaka, Nicole Meeks, Eben Rosenthal, Marisa Hom   +8 more
wiley   +1 more source

Antiepileptic Drug Combinations for Epilepsy: Mechanisms, Clinical Strategies, and Future Prospects. [PDF]

Int J Mol Sci
Li C, Wang X, Deng M, Luo Q, Yang C, Gu Z, Lin S, Luo Y, Chen L, Li Y, He B.   +10 more
europepmc   +1 more source

Systematic analysis of drug combinations against Gram-positive bacteria. [PDF]

Nat Microbiol, 2023
Cacace E, Kim V, Varik V, Knopp M, Tietgen M, Brauer-Nikonow A, Inecik K, Mateus A, Milanese A, Mårli MT, Mitosch K, Selkrig J, Brochado AR, Kuipers OP, Kjos M, Zeller G, Savitski MM, Göttig S, Huber W, Typas A.   +19 more
europepmc   +1 more source

Drug combinations and all cause mortality in heart disease: No new insights were gained [PDF]

, 2005
S Björck
openalex   +1 more source

Strategies to reduce the cancer burden and improve access to effective and affordable cancer interventions in Europe

Molecular Oncology, EarlyView.
Comprehensive cancer centre (CCCs) and CCCs of Excellence (CCCoE) integration in healthcare. Through outreach to surrounding community hospitals, CCCs enable wider access to top‐clinical cancer treatments and care, thereby facilitating the swift enrolment of patients into data‐rich clinical trials (PI‐initiated trials testing new concepts, drug ...
Anton Berns, Ulrik Ringborg, Julio Celis, Bengt Jönsson, Michael Baumann   +4 more
wiley   +1 more source

Drug Combinations Targeting FAK and MEK Overcomes Tumor Heterogeneity in Glioblastoma. [PDF]

Pharmaceutics
Furqan M, Elliott RJR, Nagle PWK, Dawson JC, Masalmeh R, Garcia VA, Munro AF, Drake C, Morrison GM, Pollard SM, Ebner D, Brunton VG, Frame MC, Carragher NO.   +13 more
europepmc   +1 more source

Drug combinations and all cause mortality in heart disease: Authors' reply [PDF]

, 2005
Julia Hippisley‐Cox, Carol Coupland
openalex   +1 more source

Genomics‐led approach to drug testing in models of undifferentiated pleomorphic sarcoma

Molecular Oncology, EarlyView.
GA text Genomic data from undifferentiated pleomorphic sarcoma patients and preclinical models were used to inform a targeted drug screen. Selected compounds were tested in 2D and 3D cultures of UPS cell lines. A combination of trametinib and infigratinib was synergistic in the majority of UPS cell lines tested, which was further confirmed in an ex ...
Piotr J. Manasterski, Molly R. Danks, John P. Thomson, Morwenna Muir, Martin Lee, John C. Dawson, Ana T. Amaral, Juan Diaz‐Martin, David S. Moura, Javier Martin‐Broto, Ali Alsaadi, Donald M. Salter, Ailsa J. Oswald, Graeme Grimes, Larry Hayward, Ted R. Hupp, Karen Sisley, Paul H. Huang, Neil O. Carragher, Valerie G. Brunton   +19 more
wiley   +1 more source

Flash optimization of drug combinations for Acinetobacter baumannii with IDentif.AI-AMR. [PDF]

NPJ Antimicrob Resist
You K, Binte Mohamed Yazid N, Chong LM, Hooi L, Wang P, Zhuang I, Chua S, Lim E, Kok AZX, Marimuthu K, Vasoo S, Ng OT, Chan CEZ, Chow EK, Ho D.   +14 more
europepmc   +1 more source